Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Public ClinicalTrials.gov record NCT04144348. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.
Study identification
- NCT ID
- NCT04144348
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 51 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Months to 49 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2019 (Actual)
- Primary completion
- Dec 20, 2022 (Actual)
- Completion
- Dec 20, 2022 (Actual)
- Last update posted
- Feb 3, 2023
2019 – 2022
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Research Associates Inc | Birmingham | Alabama | 35205 | — |
| Meridian Clinical Research | Washington D.C. | District of Columbia | 20016 | — |
| Clinical Research Prime | Idaho Falls | Idaho | 83404 | — |
| Heartland Research Associates LLC | El Dorado | Kansas | 67042 | — |
| Heartland Research Associates LLC | Newton | Kansas | 67114 | — |
| MedPharmics | Metairie | Louisiana | 70006 | — |
| Meridian Clinical Research, LLC | Lincoln | Nebraska | 68510 | — |
| Meridian Clinical Research | Norfolk | Nebraska | 68701 | — |
| Meridian Clinical Research, LLC | Omaha | Nebraska | 68134 | — |
| UHS Primary Care | Binghamton | New York | 13901 | — |
| Child Healthcare Associates | Liverpool | New York | 13090 | — |
| Child Healthcare Assoc. | Syracuse | New York | 13057 | — |
| Duke Vaccine and Trials Unit | Durham | North Carolina | 27710 | — |
| Ohio Pediatric Research Assn Inc | Dayton | Ohio | 45414 | — |
| Sanford Children's Hospital | Sioux Falls | South Dakota | 57117 | — |
| Crossroads Clinical Research | Corpus Christi | Texas | 78413 | — |
| University of Texas Medical Branch (UTMB) | Galveston | Texas | 77555 | — |
| Tekton Research Inc | San Antonio | Texas | 78240 | — |
| Tanner Clinic | Layton | Utah | 84041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04144348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04144348 live on ClinicalTrials.gov.